Articles tagged with Reperfusion
Researchers at SwRI and Trinity University are working on a new prodrug to mitigate ischemia/reperfusion injury (IRI), which causes permanent cellular and tissue damage. The team aims to protect against IRI by targeting protein misfolding during cellular stress.
Researchers have developed novel nanomaterials to combat myocardial ischemia-reperfusion injury, demonstrating significant cardioprotective effects in preclinical models. These nanoplatforms improve drug enrichment efficiency and reduce systemic toxicity, showing considerable clinical translation prospects.
Researchers analyzed data from three trials and found nerinetide provided a clinically significant benefit to patients. The findings suggest that treating early, fast, and administering the drug can lead to improved patient outcomes.
Two anti-inflammatory molecules, TGFβ1 and HpTGM, reduce the inflammatory response within the injured heart and scarring. Treatment with these proteins at the time of reperfusion reduces infarct size and mature scar size.
Researchers at UTHealth Houston are studying the impact of circadian rhythm on heart attacks and cardiac surgery, with a focus on identifying novel therapies to protect the heart. They will investigate the role of key genes and signaling pathways in modulating daytime variations in cardiac injury.
A recent study found that COVID-19 infection can lead to increased infarct growth and ongoing tissue consumption even after successful reperfusion through angiography. This suggests a potentially aggressive clinical course for patients with COVID-19 and large-vessel occlusion acute ischemic stroke.
Research found PIRI to be an independent predictor of infarct growth rate and 90-day outcomes in large-vessel occlusive stroke. The study suggests PIRI may help identify patients who could benefit from late-window endovascular thrombectomy.
A large stroke trial found that intensive blood pressure lowering after clot removal compromises the return of blood flow to the affected area, leading to more brain tissue deterioration and major disability. The study suggests that this increasingly common treatment strategy should be avoided in clinical practice.
Researchers at Ohio State University created a mathematical model that assesses the efficacy of immunomodulatory drugs in treating myocardial infarctions. The study found that certain combinations of these drug inhibitors were more efficient at reducing inflammation, offering new possibilities for improving patient outcomes.
A new study from USF Health reveals that activated protein C may help improve aging patients' tolerance to reperfusion injury, a potentially adverse effect of treatment for ischemic heart disease. The researchers suggest that drugs derived from APC may limit ischemia and reperfusion-induced heart damage.
A study by Indiana University School of Medicine researchers suggests that reperfusion therapy may not be as effective in halting muscle damage during heart attacks as previously thought. The team's findings indicate that internal bleeding within the heart muscle can continue to cause damage even after the blocked coronary artery is op...
The new guideline recommends a patient-centric approach to managing patients with coronary artery disease, incorporating clinical indications and multidisciplinary team decision-making. The guideline aims to improve quality of care and reduce disparities in treatment, particularly among women and underrepresented racial or ethnic groups.
Scientists from Japan discover IL-36Ra plays a pivotal role in wound healing, and Cl-amidine normalizes exacerbated I/R injury. The study's findings suggest IL-36Ra as a potential therapeutic target for cutaneous I/R injuries.
A new locally acting treatment aims to reduce the severity of post-transplant ischemia reperfusion injury (IRI) without affecting the immune system. The treatment targets specific neoepitopes exposed on injured donor organs, reducing the risk of organ rejection and improving transplant outcomes.
A preclinical study found that age-related decline in two sirtuin enzymes alters mitochondrial dynamics, weakening cardiac contractions in response to ischemia-reperfusion injury. Boosting SIRT1/SIRT3 levels may help protect against such injuries, potentially reducing heart attack complications and deaths.
A new study has successfully performed heart transplants using donation after cardiac death with normothermic regional perfusion, increasing cardiac allograft availability by 20-30%. The procedure allows for immediate reperfusion and assessment of the heart prior to transplantation, improving outcomes for patients.
Researchers at Medical University of South Carolina report that adding a compound to reduce inflammation improves learning, memory and motor recovery after stroke. The treatment may also extend the treatment window by reducing risk of hemorrhage.
New Jersey researchers found that early reperfusion of the left reading network correlates with improved reading and language competence in people recovering from left-sided stroke. The study also showed that increased perfusion of the right reading network is associated with worse reading performance, challenging previous beliefs.
Researchers found that initiating stroke treatment just 15 minutes faster can save lives and prevent disability. Busier hospitals, which treat more than 450 people for stroke each year, have better outcomes than those that treat fewer patients per year.
Researchers found that a specific esmolol-epinephrine ratio can provide cardioprotection while maintaining hemodynamic activity during myocardial ischemia and reperfusion injury. This combination therapy may be beneficial in treating patients with cardiogenic shock or cardiac arrest.
Researchers at Johns Hopkins Medicine have discovered a new compound called rapadocin that may prevent reperfusion injury, a tissue-damaging complication of surgery. The compound was found to block the activity of a chemical pathway associated with reperfusion injuries, reducing markers of kidney damage in mice.
The article discusses how reperfusion injury amplifies cell damage after tissue perfusion. Calcium handling mechanisms, including Ca2+ ion elevation, predispose patients to mitochondrial failure, hyper-contracture, and proteolysis.
Researchers developed a novel model to study liver transplantation reperfusion and its impact on organ function. The new technique simulates the reperfusion stage of transplantation, allowing for better understanding of organ preservation and potential improvements in liver transplantation outcomes.
Researchers developed a model predicting heart cells' ability to produce ATP and stay alive under low oxygen conditions. The study found that even severely depleted regions of the heart can maintain ATP levels using energy reserves until oxygen approaches zero, but eventually crash when backup reserves shut down.
A recent study found that patients who did not receive reperfusion therapy had a significantly higher 30-day mortality rate, regardless of the type of hospital they were treated in. The researchers emphasized the importance of improving healthcare systems to facilitate timely treatment and reduce delays.
A large clinical trial found that ischemic postconditioning did not reduce death from any cause or hospitalization for heart failure in STEMI patients, but improved left ventricular ejection fraction in a specific subgroup.
Delays in restoring blood flow after a stroke were associated with decreased benefits of intra-arterial clot-busting treatment and reduced chances for a good outcome. The chances for a good outcome were reduced by 6 percent for every hour of reperfusion delay.
A new study published in the Journal of Parenteral and Enteral Nutrition found that intravenous glutamine administration immediately after lower limb ischemia reduced inflammatory reactions locally and systemically. The study showed that GLN decreased gene expressions of inflammatory mediators, blood macrophage percentages, and plasma ...
A new study published in PLOS ONE suggests that a dose of iodide can significantly reduce the damage caused by reperfusion injury after a heart attack. The study found that intravenous infusions of sodium iodide reduced myocardial infarction damage by up to 75 percent in mice, and oral iodide showed similar protective effects.
A European study found that experimental agent TRO40303 was ineffective in preventing tissue damage when impaired blood flow is corrected in patients with acute ST-elevation myocardial infarction. The study suggests that high-quality modern care may leave little room for improvement in STEMI treatment.
The NOMI trial found that nitric oxide inhalation improved cardiac recovery, particularly in patients who had not previously received nitroglycerin. However, it did not reduce infarct size. The study suggests that further investigation is warranted for STEMI patients.
The study reveals rutaecarpine's ability to improve neurological function after cerebral ischemia reperfusion injury. The mechanism involves reducing oxidative stress, providing a promising basis for rutaecarpine as an ideal drug for preventing and treating cerebral ischemia reperfusion injury.
Researchers found that oleuropein aglycone, a compound in olive oil, significantly reduces inflammation and tissue damage caused by intestinal ischemia and reperfusion injury. The study suggests potential therapeutic benefits for patients with spinal cord injuries, arthritis, and pleurisy.
The study found a decline in mortality rates among STEMI patients in France from 1995 to 2010, attributed to increased use of reperfusion therapy and recommended treatments. The proportion of younger women with STEMI also increased, consistent with declining prevalence of hypertension, diabetes, and hypercholesterolemia.
A 15-year study of French registries shows a 68% decrease in STEMI mortality rate, with key factors including younger patients, increased use of reperfusion therapy, and improved early management. The results highlight the importance of addressing population characteristics and behavior to further reduce mortality rates.
Research published in the Journal of NeuroInterventional Surgery found that high volume endovascular stroke centers have faster times to treatment, higher reperfusion rates, and improved clinical outcomes. Patients treated at these centers are more likely to have blood flow restored and survive
A study found that patients with blood potassium levels between 3.5 and less than 4.5 mEq/L had a lower risk of death than those with levels higher or lower than this range after a heart attack. The optimal range of serum potassium levels in AMI patients may be between 3.5 and 4.5 mEq/L.
A study of 30,077 STEMI patients found that the gender gap in treatment and mortality has not diminished over two time periods. Adherence to guidelines needs to be increased for women with STEMI to improve prognosis.
A study found that only 11% of patients with STEMI receive primary PCI within 30 minutes, leading to delayed treatment and worse outcomes. Patients who received timely transfers were more likely to undergo primary PCI and had better door-to-balloon times.
A study found that long-term cumulative mortality was highest among patients with system delays of 121-180 minutes, increasing by 28.1% and 30.8% respectively. System delay was independently associated with mortality in multivariate analysis.
Patients who received treatment beyond recommended times for heart attacks had a significantly increased risk of death within 30 days. Treatment within recommended delays was associated with lower mortality rates, with each 10% increase in timely treatment linked to a decrease in 30-day mortality.
Acute myocardial infarction (AMI) is a leading cause of death in the Western world, with prevalence expected to rise in developing countries. Primary PCI can open more vessels than thrombolytic therapy, saving more lives but requiring specialized facilities and collaboration.
Effective reperfusion therapy in AMI patients can cut individual risk of dying by half and save millions of European lives. Modern catheter-based reperfusion strategies are more effective than fibrinolytic agents, reducing infarct-related mortality by up to 37%.
The NORDISTEMI study found that patients in rural areas with long transfer delays experience improved treatment outcomes with thrombolysis followed by immediate angiography. The results suggest an early invasive strategy may be preferable to conservative management, reducing the risk of death, reinfarction, or stroke.
Researchers characterized early-stage liver reperfusion injury mechanisms using rats with varying ischemia-reperfusion periods. Key findings include cell vacuolation, bleb formation, and apoptosis induction.
The Stent 4 Life campaign targets reperfusion therapy with percutaneous coronary interventions (PCI) to reduce STEMI patient mortality. It encourages the application of PCI above 600 per million population in Europe, aiming to address most STEMI patients' needs.
The document provides a comprehensive assessment of care by establishing new performance measures, including the importance of acute reperfusion therapy and the need for accountability in providing timely treatment. It also addresses concerns about exclusion criteria and the determination of when measurement stops.
A study found that Nigella sativa reduces liver enzyme levels and oxidative stress after ischemia-reperfusion injury. The treatment also showed improved histopathology in liver tissue, suggesting its potential as a therapeutic agent for hepatic ischemia reperfusion injury.
Researchers developed a novel method using human embryonic stem cell secretions to reduce tissue injury after a heart attack. The approach significantly improved heart function and reduced tissue death by 60%, offering a promising therapeutic option for heart attack patients.
The Phase II clinical trial of FX06 showed a statistically significant reduction in myocardial necrosis following intravenous application concurrent with reperfusion. The peptide preserves blood vessel function by binding to VE-cadherin, leading to reduced inflammation and infarct sizes.
Researchers discovered that fruit flies experience irreversible damage to their respiratory systems when exposed to brief bursts of oxygen after being starved of oxygen. This model provides a low-cost alternative for studying reperfusion injury, potentially leading to faster progress in mitigating its effects on humans.
The study found that patients who arrived at the hospital within one to two hours of onset had a 77% higher rate of receiving reperfusion therapy, compared to those who waited 11-12 hours. Delayed arrival resulted in lower rates of reperfusion therapy and poorer treatment outcomes.
A statewide program in North Carolina significantly improved the rate of coronary reperfusion for heart attack patients, reducing median door-in to door-out times by up to 49 minutes. While clinical outcomes remained unchanged, the study demonstrates that coordination of care can improve quality of care.
A new study found that emergency angioplasty treatment for heart attacks has increased dramatically over the last decade, with a notable decline in patients going without crucial care. However, 10% of eligible patients still do not receive this urgent treatment, highlighting gaps in care for certain subgroups.
The AMI-QUEBEC Study found that almost half of patients received fibrinolytic therapy within 30 minutes, a significant improvement from previous times. Door-to-balloon times remained a concern, exceeding recommended times in most cases.
Researchers found that combining antioxidants with a chest pain drug improves heart function after a heart attack by reducing free radical damage. The antioxidant derivatives TMZ-NH and TMZ-NH showed significant protection against tissue damage during reperfusion, leading to improved blood flow and reduced infarct size.
The ESC has issued a policy statement on reperfusion therapy for STEMI treatment, highlighting the importance of early diagnosis and timely initiation of therapy. The statement recommends prioritizing primary PCI and thrombolytic treatment within three hours of symptom onset.
A study found persistent racial and gender disparities in heart attack care, with black women having lower rates of reperfusion therapy and higher in-hospital mortality rates compared to white men. The differences were not explained by patient characteristics, raising concerns about under-treatment.
Patients arriving at hospitals outside regular hours had significantly higher mortality rates compared to those arriving during daytime. Longer reperfusion treatment times were the primary cause of these differences, according to a recent study examining STEMI patients treated with fibrinolytic therapy or PCI.
Researchers found that invasive treatment with primary percutaneous coronary intervention (PCI) resulted in smaller infarct size and lower risk of death or stroke compared to conventional conservative treatment. This suggests that reperfusion therapy may be beneficial for patients presenting late after symptom onset.